COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,046 Articles (22,627 medRxiv, 8,419 bioRxiv)

Most recent first Previous |  Page 893: Articles 8921-8930  | Next

A role for Nucleocapsid-specific antibody function in Covid-19 Convalescent plasma therapy
Herman, J. D., Wang, C., Burke, J. S., Zur, Y., Compere, H., Kang, J., Macvicar, R., Shin, S., Frank, I., Siegel, D., Tebas, P., Choi, G. H., Shaw, P. A., Yoon, H., Pirofski, L.-a., Juelg, B., Bar, K. J., Lauffenburger, D., Alter, G.
10.1101/2022.02.19.22271230 — Posted: 2022-02-22
Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting
Rane, M. S., Robertson, M., Kulkarni, S., Frogel, D., Gainus, C., Nash, D.
10.1101/2022.02.21.22271298 — Posted: 2022-02-22
Childhood Trauma Exposure Increases Long COVID Risk
Villanueva van den Hurk, A. W., Ujvari, C., Greenspan, N., Malaspina, D., Jimenez, X. F., Walsh-Messinger, J.
10.1101/2022.02.18.22271191 — Posted: 2022-02-22
Tackling the first COVID-19 wave at the Cape Town Hospital of Hope: Why was it such a positive experience for staff?
Reid, S., Nana, M., Abrahams, T., Von Pressentin, K., Okun, R., Ras, T., Hussey, N.
10.1101/2022.02.21.22271306 — Posted: 2022-02-22
Community-based Case Studies of Vaccine Hesitancy and the COVID-19 Response in South Africa; The VaxScenes Study
Wiysonge, C. S., Coulson, N., Pillay, N., Cooper, S., Groenewald, C., Essack, Z., Parker, S., Houston, G., Simmonds, J., Jaca, A., Mutemwa, M., Katoto, P. D., Rooyen, H. v.
10.1101/2022.02.21.22271272 — Posted: 2022-02-22
Using Best-Worst Scaling to investigate younger adult Canadians' preferences for COVID-19 vaccination and public health measures: an observational study
Tatar, O., Haward, B., Zhu, P., Griffin-Mathieu, G., Perez, S., Zimet, G., Rosberger, Z.
10.1101/2022.02.18.22271180 — Posted: 2022-02-22
Bayesian Emulation and History Matching of JUNE
Vernon, I., Owen, J., Aylett-Bullock, J., Cuesta-Lazaro, C., Frawley, J., Quera-Bofarull, A., Sedgewick, A., Shi, D., Truong, H., Turner, M., Walker, J., Caulfield, T., Fong, K., Krauss, F.
10.1101/2022.02.21.22271249 — Posted: 2022-02-22
COVID infection rates, clinical outcomes, and racial/ethnic and gender disparities before and after Omicron emerged in the US
Xu, R., Wang, L., berger, N. A., davis, p. B., Kaelber, D. C., Volkow, N. D.
10.1101/2022.02.21.22271300 — Posted: 2022-02-22
Edible formulations of chicken egg derived IgY antibodies neutralize SarsCoV2 Omicron RBD binding to human ACE2
Meher, K., Sivakumar, S., Kadiyala, G., Iyer, S., Vangala, S., Chandran, S., Saxena, U.
10.1101/2022.02.21.481267 — Posted: 2022-02-22
A novel intranasal administration adenoviral vector-based platform for rapid COVID-19 vaccine development
Yuan, Y., Gao, X., Ni, F., Xie, W., Fu, W., Zhang, G., Hu, H., Li, Y., Hu, Q., Huang, C., Liu, B., Liu, Y., Shen, Q., Liang, M.
10.1101/2022.02.21.481247 — Posted: 2022-02-22

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).